Cancer is a dreaded and often fatal disease. However, given today’s treatment options, outcomes could potentially be greatly improved if more cancers were detected in early stages and treatments were better tailored to individual patients’ needs. This widely unmet medical need makes IVD (in vitro diagnostic) tests for cancer a segment with high future growth potential in the multi-billion euro molecular diagnostics market.

Epigenomics is a molecular diagnostics company focusing on the development and commercialization of in vitro diagnostic tests for cancer.

Our screening tests aim at finding cancer at early stages before symptoms occur and are carried out conveniently on body fluids such as blood plasma or urine. These tests potentially address millions of individuals in each of the major markets such as the United States, Europe, and Japan and provide product opportunities each with peak sales potentials of several hundred millions of euros for diagnostics companies worldwide. Our lead screening test development program is in colorectal cancer. Further screening test are in development for prostate and lung cancer.

The concept of our diagnostic tests in development relies on detecting differences in DNA methylation patterns between healthy and sick individuals or between subgroups of patients for disease classification. We believe that we are an industry leader in DNA methylation technologies and biomarkers.

Industry partners as well as the medical and life science communities can access or intellectual property portfolio of about 150 filed patent families covering DNA methylation technologies and biomarkers as well as our DNA methylation expertise through research products, biomarker services, IVD development collaborations, and licensing.